INSR and non-small cell lung carcinoma: INSR, has been used as a biomarker for prognosis of non-small cell lung cancer and an INSR protein inhibitor, Zykadia, has been authorized by U.S. Food and Drug Administration (FDA) [85] and European Medicines Agency [86] as a treatment of advanced ALK-positive non-small cell lung cancer [87].